Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 21

1.

Influence of epidermal growth factor receptor expression on the cetuximab and panitumumab response rates of head and neck carcinoma cells.

Hartmann S, Seher A, Brands RC, Linz C, Lessner G, Böhm H, Kübler AC, Müller-Richter UD.

J Craniomaxillofac Surg. 2014 Apr 2. pii: S1010-5182(14)00098-5. doi: 10.1016/j.jcms.2014.03.018. [Epub ahead of print]

PMID:
24780353
[PubMed - as supplied by publisher]
2.

TNF Receptor-Associated Factor 1 is a Major Target of Soluble TWEAK.

Carmona Arana JA, Seher A, Neumann M, Lang I, Siegmund D, Wajant H.

Front Immunol. 2014 Feb 18;5:63. doi: 10.3389/fimmu.2014.00063. eCollection 2014.

PMID:
24600451
[PubMed]
Free PMC Article
3.

Fibroblast growth factor inducible (Fn14)-specific antibodies concomitantly display signaling pathway-specific agonistic and antagonistic activity.

Salzmann S, Seher A, Trebing J, Weisenberger D, Rosenthal A, Siegmund D, Wajant H.

J Biol Chem. 2013 May 10;288(19):13455-66. doi: 10.1074/jbc.M112.435917. Epub 2013 Mar 26.

PMID:
23532848
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Novel features of ARS selection in budding yeast Lachancea kluyveri.

Liachko I, Tanaka E, Cox K, Chung SC, Yang L, Seher A, Hallas L, Cha E, Kang G, Pace H, Barrow J, Inada M, Tye BK, Keich U.

BMC Genomics. 2011 Dec 28;12:633. doi: 10.1186/1471-2164-12-633.

PMID:
22204614
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Studies of binding of tumor necrosis factor (TNF)-like weak inducer of apoptosis (TWEAK) to fibroblast growth factor inducible 14 (Fn14).

Fick A, Lang I, Schäfer V, Seher A, Trebing J, Weisenberger D, Wajant H.

J Biol Chem. 2012 Jan 2;287(1):484-95. doi: 10.1074/jbc.M111.287656. Epub 2011 Nov 11.

PMID:
22081603
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Gene expression profiling of connective tissue growth factor (CTGF) stimulated primary human tenon fibroblasts reveals an inflammatory and wound healing response in vitro.

Seher A, Nickel J, Mueller TD, Kneitz S, Gebhardt S, ter Vehn TM, Schlunck G, Sebald W.

Mol Vis. 2011 Jan 8;17:53-62.

PMID:
21245951
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Soluble and transmembrane TNF-like weak inducer of apoptosis differentially activate the classical and noncanonical NF-kappa B pathway.

Roos C, Wicovsky A, Müller N, Salzmann S, Rosenthal T, Kalthoff H, Trauzold A, Seher A, Henkler F, Kneitz C, Wajant H.

J Immunol. 2010 Aug 1;185(3):1593-605. doi: 10.4049/jimmunol.0903555. Epub 2010 Jul 7.

PMID:
20610643
[PubMed - indexed for MEDLINE]
Free Article
8.

Receptor oligomerization and beyond: a case study in bone morphogenetic proteins.

Heinecke K, Seher A, Schmitz W, Mueller TD, Sebald W, Nickel J.

BMC Biol. 2009 Sep 7;7:59. doi: 10.1186/1741-7007-7-59.

PMID:
19735544
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Crystal structure analysis reveals a spring-loaded latch as molecular mechanism for GDF-5-type I receptor specificity.

Kotzsch A, Nickel J, Seher A, Sebald W, Müller TD.

EMBO J. 2009 Apr 8;28(7):937-47. doi: 10.1038/emboj.2009.37. Epub 2009 Feb 19.

PMID:
19229295
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Connective tissue growth factor does not affect transforming growth factor-beta 1-induced Smad3 phosphorylation and T lymphocyte proliferation inhibition.

Kunzmann S, Seher A, Kramer BW, Schenk R, Schütze N, Jakob F, Sebald W, Speer CP.

Int Arch Allergy Immunol. 2008;147(2):152-60. doi: 10.1159/000137284. Epub 2008 Jun 6.

PMID:
18535390
[PubMed - indexed for MEDLINE]
11.

Structure analysis of bone morphogenetic protein-2 type I receptor complexes reveals a mechanism of receptor inactivation in juvenile polyposis syndrome.

Kotzsch A, Nickel J, Seher A, Heinecke K, van Geersdaele L, Herrmann T, Sebald W, Mueller TD.

J Biol Chem. 2008 Feb 29;283(9):5876-87. Epub 2007 Dec 26.

PMID:
18160401
[PubMed - indexed for MEDLINE]
Free Article
12.

Type I receptor binding of bone morphogenetic protein 6 is dependent on N-glycosylation of the ligand.

Saremba S, Nickel J, Seher A, Kotzsch A, Sebald W, Mueller TD.

FEBS J. 2008 Jan;275(1):172-83. Epub 2007 Dec 6.

PMID:
18070108
[PubMed - indexed for MEDLINE]
13.

A silent H-bond can be mutationally activated for high-affinity interaction of BMP-2 and activin type IIB receptor.

Weber D, Kotzsch A, Nickel J, Harth S, Seher A, Mueller U, Sebald W, Mueller TD.

BMC Struct Biol. 2007 Feb 12;7:6.

PMID:
17295905
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

[Biological effect of hydrated and esterified fats].

Seher A.

Bibl Nutr Dieta. 1985;(34):94-109. German. No abstract available.

PMID:
3970686
[PubMed - indexed for MEDLINE]
15.

Preparation and physiological properties of alkyl esters of 2,3-dihydroxypropionic acid.

Seher A, Weiss U.

Chem Phys Lipids. 1981 Sep;29(2):157-64.

PMID:
6456845
[PubMed - indexed for MEDLINE]
16.

[A new contrast medium emulsion for lymphography (author's transl)].

Roth SL, Dombrowski H, Hiort U, Kalbfleisch H, Ludwig K, Siefart F, Seher A, Vielhauer E.

Rofo. 1979 Sep;131(3):317-21. German.

PMID:
161269
[PubMed - indexed for MEDLINE]
17.

[Solubility of phospholipids in oilseeds depending on the extraction conditions (author's transl)].

Seher A, Moon CK.

Z Lebensm Unters Forsch. 1978 Aug 30;167(2):82-6. German.

PMID:
706808
[PubMed - indexed for MEDLINE]
18.

[Newer trends in the technology of fats].

Seher A.

Bibl Nutr Dieta. 1971;16:76-100. German. No abstract available.

PMID:
5113486
[PubMed - indexed for MEDLINE]
19.

[On the knowledge of the addition of mercuriacetate to mono- and di-alkyne acids].

SEHER A.

Mitt Dtsch Pharm Ges Pharm Ges DDR. 1959 Oct;29:519-28. German. No abstract available.

PMID:
13858580
[PubMed - indexed for MEDLINE]
20.

[Determination of the iodine number].

SEHER A, ARENDS W.

Mitt Lebensmittelunters Hyg. 1957;48(1):1-4. German. No abstract available.

PMID:
13430594
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk